Data Provide Additional Insight Into the Mode of Action of MAVENCLAD(TM) (Cladribine Tablets) in Patients With Relapsing MS

DARMSTADT, Germany, June 26, 2017 /PRNewswire/ --


- Data suggest that MAVENCLAD(TM) (Cladribine Tablets) selectively and
discontinuously reduces B and T lymphocytes, with lymphocyte counts returning to
normal range before the end of Year 2
- The lymphocyte data presented at EAN Congress are consistent with other clinical
safety presentations of MAVENCLAD(TM) (Cladribine Tablets) at the congress 


Merck, a leading science and technology company, today announced the presentation of safety and efficacy data on MAVENCLAD(TM) (Cladribine Tablets) for the treatment of relapsing MS at the 3rd Congress of the European Association of Neurology (EAN), in Amsterdam, the Netherlands. Data from the placebo-controlled CLARITY, CLARITY Extension and ORACLE-MS clinical trials support the benefit: risk profile of Cladribine Tablets that have prompted an application for marketing authorisation in the EU, and the recent positive opinion from the Committee for Medicinal Products for Human Use (CHMP).

(Logo: http://photos.prnewswire.com/prnh/20170421/492737LOGO )

In these studies, Cladribine Tablets was administered as two annual treatment courses in Years 1 and 2, with a total maximum of 20 days of oral treatment equal to a dose of 3.5 mg/kg body weight, followed by no further active treatment in Years 3 and 4.

"These data presented at EAN Congress 2017 bring the MS treating community closer to understanding the mechanism of action of Cladribine Tablets," said Professor Per Soelberg Sørensen, presenting author and Head of MS Research Unit, Danish Multiple Sclerosis Centre. "These data support the emerging theories around the ability of some agents to selectively 'reset' the immune system without the secondary autoimmunity that we sometimes see with treatments for relapsing MS. This would represent a significant advance in the field."

Data from three key studies suggest that Cladribine Tablets selectively and discontinuously reduce both B and T lymphocytes in patients with early and relapsing forms of MS. An early and discontinuous reduction of peripheral blood B cells was seen, with cells numbers reaching a nadir at 13 weeks after treatment, followed by a rapid reconstitution toward baseline. A moderate reduction in T cell counts was also shown, although to a lesser degree than B cells; this reduction was more pronounced in CD4+ than CD8+ lymphocytes.

An exploratory analysis of the CLARITY data suggests that if strict lymphocyte count rules are adhered to before each yearly short course treatment, then the proportion of patients recovering at the end of Year 1 was 89.1% and at the end of Year 2 was 88.3%. Given the clinical effect observed during Years 1 and 2 of dosing in CLARITY, and beyond Years 1 and 2 with CT 3.5 mg/kg in CLARITY EXT, these data demonstrate that the clinical effect observed is achieved without continuous immunosuppression and through selective effects on B and T cell populations.

"Following last week's positive CHMP opinion, this integrated safety data, including 8 years of follow up in some patients, further supports the use of Cladribine Tablets as a treatment option for patients with MS," said Luciano Rossetti, Global Head of R&D for the biopharma business of Merck.

On 23 June, the Committee for Medicinal Products for Human Use (CHMP) granted a positive opinion on the use of Cladribine Tablets for relapsing MS, and this recommendation has been passed on to the European Commission (EC) to make the final decision on the Marketing Authorization Application (MAA) later this year.

Lymphopenia was the most commonly reported adverse event (AE) in patients treated with Cladribine Tablets. The incidence of infections was 48.3% with Cladribine Tablets and 42.5% with placebo, with 99.1% and 99.0% rated mild-to-moderate by investigators.

MAVENCLAD(TM) is the proprietary name submitted to EMA for the investigational medicine Cladribine Tablets.

About MAVENCLAD(TM) (Cladribine Tablets) 

Cladribine Tablets is a short-course oral therapy that is believed to selectively and periodically target lymphocytes thought to be integral to the pathological process of MS. Cladribine Tablets is currently under clinical investigation and not yet approved for the treatment for any use in the United States, Canada and Europe. In June 2017, the Committee for Medicinal Products for Human Use (CHMP) granted a positive opinion on the use of Cladribine Tablets for highly active relapsing MS, and this recommendation has been passed on to the EC to make the final decision on the Marketing Authorization Application (MAA) later this year.

The clinical development program for Cladribine Tablets includes:


- The CLARITY (CLAdRIbine Tablets Treating MS OrallY) study: a two-year Phase III
placebo-controlled study designed to evaluate the efficacy and safety of MAVENCLAD as
a monotherapy in patients with RRMS.
- The CLARITY extension study: a four-year Phase III placebo-controlled study following
on from the CLARITY study, designed to evaluate the safety and efficacy of MAVENCLAD
over an extended administration for four years.
- CLARITY (CLAdRIbine Tablets Treating MS OrallY) study and its extension: a two-year
Phase III placebo-controlled study designed to evaluate the efficacy and safety of
Cladribine Tablets as a monotherapy in patients with RRMS and its two-year extension
designed to provide data on the long-term safety and efficacy of extended
administration of Cladribine Tablets for up to four years.
- ORACLE MS (ORAl CLadribine in Early MS) study: a two-year Phase III placebo-controlled
study designed to evaluate the efficacy and safety of Cladribine Tablets as a
monotherapy in patients at risk of developing MS (patients who have experienced a
first clinical event suggestive of MS).
- ONWARD (Oral Cladribine Added ON To Interferon beta-1a in Patients with Active
Relapsing Disease) study: a Phase II placebo-controlled study designed primarily to
evaluate the safety and tolerability of adding Cladribine Tablets treatment to
patients with relapsing forms of MS, who have experienced breakthrough disease while
on established interferon-beta therapy.
- PREMIERE (Prospective Observational Long-term Safety Registry of Multiple Sclerosis
Patients Who Have Participated in Cladribine Clinical Studies) study: interim
long-term follow-up data from the prospective registry, PREMIERE, to evaluate the
safety and efficacy of Cladribine Tablets. The follow-up will consist of over 10,000
patient years of exposure in total, with follow-up in some patients exceeding eight
years at completion.


About Multiple Sclerosis 

Multiple sclerosis (MS) is a chronic, inflammatory condition of the central nervous system and is the most common, non-traumatic, disabling neurological disease in young adults. It is estimated that approximately 2.3 million people have MS worldwide. While symptoms can vary, the most common symptoms of MS include blurred vision, numbness or tingling in the limbs and problems with strength and coordination. The relapsing forms of MS are the most common.

All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to http://www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

About Merck 

Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life - from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2016, Merck generated sales of EUR 15.0 billion in 66 countries.

Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.



Photo:
http://photos.prnewswire.com/prnh/20170421/492737LOGO




CONTACT: Erin-Marie Beals, +49-151-1454-2694

PR Newswire

Dit persbericht is via ANP Pers Support naar internationale (vak en online) media gestuurd. Heb je nieuws voor buitenlandse journalisten? Bekijk dan onze mogelijkheden of neem contact met ons op.

Verstuur nu éénmalig een persbericht

Verstuur persberichten en beeldmateriaal naar redacties in binnen- en buitenland. Via het ANP-net, het internationale medianetwerk van PR Newswire of met een perslijst op maat.

Direct persbericht versturen
070 - 41 41 234